CV Sciences, Inc. (CVSI) stock
CVSIOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-21.13%)
Close on Oct 19, 2026Market cap $2.53MP/E –Yield –
CV Sciences r&d expenses
Research and development expenses are spending on new products and technology.
CV Sciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $73.00K, down 43.4% year over year. For fiscal 2025 it was $122.00K, up 3.4% from the year before. Over ten years it grew -21.2% a year on average. The highest annual figure on record is $5.88M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $122.00K | +3.4% |
| FY2024 | Dec 31, 2024 | $118.00K | -21.9% |
| FY2023 | Dec 31, 2023 | $151.00K | -50.8% |
| FY2022 | Dec 31, 2022 | $307.00K | -74.1% |
| FY2021 | Dec 31, 2021 | $1.19M | -59.7% |
| FY2020 | Dec 31, 2020 | $2.94M | -49.9% |
| FY2019 | Dec 31, 2019 | $5.88M | +211.8% |
| FY2018 | Dec 31, 2018 | $1.89M | +160.4% |
| FY2017 | Dec 31, 2017 | $724.00K | -37.5% |
| FY2016 | Dec 31, 2016 | $1.16M | -12.2% |
| FY2015 | Dec 31, 2015 | $1.32M | +32.1% |
| FY2014 | Dec 31, 2014 | $999.28K | +90.5% |
| FY2013 | Dec 31, 2013 | $524.48K | – |
| FY2012 | Dec 31, 2012 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $19.00K | -20.8% |
| Q2 FY2026 | Jun 30, 2026 | $18.00K | -64.0% |
| Q1 FY2026 | Mar 31, 2026 | $18.00K | -40.0% |
| Q4 FY2025 | Dec 31, 2025 | $18.00K | -28.0% |
| Q3 FY2025 | Sep 30, 2025 | $24.00K | -17.2% |
| Q2 FY2025 | Jun 30, 2025 | $50.00K | +78.6% |
| Q1 FY2025 | Mar 31, 2025 | $30.00K | -16.7% |
| Q4 FY2024 | Dec 31, 2024 | $25.00K | -37.5% |
| Q3 FY2024 | Sep 30, 2024 | $29.00K | -27.5% |
| Q2 FY2024 | Jun 30, 2024 | $28.00K | -22.2% |
| Q1 FY2024 | Mar 31, 2024 | $36.00K | +2.9% |
| Q4 FY2023 | Dec 31, 2023 | $40.00K | 0.0% |
| Q3 FY2023 | Sep 30, 2023 | $40.00K | -9.1% |
| Q2 FY2023 | Jun 30, 2023 | $36.00K | -64.7% |
| Q1 FY2023 | Mar 31, 2023 | $35.00K | -71.1% |
| Q4 FY2022 | Dec 31, 2022 | $40.00K | -89.0% |
| Q3 FY2022 | Sep 30, 2022 | $44.00K | -89.3% |
| Q2 FY2022 | Jun 30, 2022 | $102.00K | -54.7% |
| Q1 FY2022 | Mar 31, 2022 | $121.00K | -34.9% |
| Q4 FY2021 | Dec 31, 2021 | $364.00K | +31.9% |
| Q3 FY2021 | Sep 30, 2021 | $410.00K | -0.5% |
| Q2 FY2021 | Jun 30, 2021 | $225.00K | -69.8% |
| Q1 FY2021 | Mar 31, 2021 | $186.00K | -87.7% |
| Q4 FY2020 | Dec 31, 2020 | $276.00K | -78.8% |
| Q3 FY2020 | Sep 30, 2020 | $412.00K | -73.3% |
| Q2 FY2020 | Jun 30, 2020 | $746.00K | -55.8% |
| Q1 FY2020 | Mar 31, 2020 | $1.51M | +12.4% |
| Q4 FY2019 | Dec 31, 2019 | $1.30M | +71.4% |
| Q3 FY2019 | Sep 30, 2019 | $1.54M | +191.3% |
| Q2 FY2019 | Jun 30, 2019 | $1.69M | +281.9% |
| Q1 FY2019 | Mar 31, 2019 | $1.34M | +771.4% |
| Q4 FY2018 | Dec 31, 2018 | $760.00K | +405.7% |
| Q3 FY2018 | Sep 30, 2018 | $530.00K | +195.5% |
| Q2 FY2018 | Jun 30, 2018 | $442.00K | +114.9% |
| Q1 FY2018 | Mar 31, 2018 | $154.00K | -18.4% |
| Q4 FY2017 | Dec 31, 2017 | $150.30K | -46.2% |
| Q3 FY2017 | Sep 30, 2017 | $179.34K | – |
| Q2 FY2017 | Jun 30, 2017 | $205.65K | – |
| Q1 FY2017 | Mar 31, 2017 | $188.72K | – |
| Q4 FY2016 | Dec 31, 2016 | $279.41K | – |
See a number that looks wrong?